Vaccines

Following the elimination of personal belief exemptions, the statewide rate of kindergartners without up-to-date status for required vaccinations decreased from 9.84% in 2013 to 4.87% in 2017.

ACIP voted 10-to-4 to expand the recommended HPV vaccine “catch-up” age for men from 21 to 26, matching the existing guidelines for women.

Diversity of Group A Streptococcus strains has frustrated vaccine development efforts, but investigators have taken a step closer to finding a common gene signature in nearly all strains.

International travel and poor vaccine uptake are among the key factors identified by investigators who mapped counties at-risk for measles cases in the United States.

Following a rise in sexually transmitted infection diagnoses in recent years, NIAID is awarding grants for research into syphilis, gonorrhea, and chlamydia vaccine candidates.

The rate of health care-associated influenza cases per season decreased from a median of 16.8 cases pre-policy rollout to 5.2 cases post-policy rollout at a large pediatric hospital.

An Italian study found that immunization rates are high among health workers, but an important proportion of employees are not immune to mumps.

Contagion® caught up with William Schaffner, MD, medical director of the National Foundation for Infectious Diseases, to discuss the highlights from this week’s NFID Annual Conference on Vaccinology Research.

An intradermal Ebola vaccine candidate shows promise as a safe, temperature-stable, and effective option for preventing outbreaks, new data show.

The latest case cluster in the United States has led a university to change policy regarding the MMR vaccine.

To shed light on the current measles outbreaks, Contagion® is launching a video series featuring the perspectives of 2 medical experts.

Countries around the world begin to respond to measles outbreaks, with Italy taking the step of keeping unvaccinated kids home from school.

With 206 cases of measles reported so far in 11 states in 2019, a new study noting that there is no connection between the measles, mumps, rubella (MMR) vaccine and autism has been released.

The rise of Shingrix as a first-choice prophylaxis for shingles has lead to increased demand as the manufacturer commits to ramping up production.

Vaccine-preventable disease outbreaks are on the rise and social media has a responsibility to help rein it in

With 6 ongoing outbreaks, cases reported across 10 states, and the FDA commissioner contemplating federal intervention, measles remains at the forefront of collective consciousness.

As flu activity remains elevated in all regions of the United States for the fifth week in a row, a new study quantifies the impact of flu vaccination last season.

Post-licensure safety data on recombinant zoster vaccine (Shingrix) is consistent with pre-licensure clinical trial data, although the CDC cautions that the immunization is still in the “early uptake period.”

The FDA approved the vaccine in 2016 for adults between the ages of 18 and 64 who are traveling to areas of active cholera transmission.

With early season flu vaccination rates up from 2017-2018 early season rates, new pediatric influenza deaths around the country are prompting health officials to call for even higher vaccination rates.

The vaccine is approved as a 3-dose series, which consists of a 0.5 mL intramuscular injection, administered at 2, 4, and 6 months of age.

TY014 is the first candidate drug to be evaluated in clinical trials for the treatment of yellow fever.

The results of a new Dutch study suggest a rationing protocol does not diminish the effectiveness of the vaccine.

A new survey has found that 34% of US parents are not planning to have their child vaccinated against influenza.

Investigators have found that children who received a flu shot in consecutive years did not see a decline in vaccine effectiveness.

Keeping communities safe from potentially deadly viruses is everyone’s responsibility.

New outbreaks of rubella and troubling data on influenza highlight the importance of vaccination.

Sanofi Pasteur’s dengue vaccine (Dengvaxia) is moving one step closer to being approved in the United States as the FDA just accepted a Biologics License Application for the vaccine.

In 2017, 47 outbreak cases of mumps were reported in the Denver Metropolitan area among individuals who attended Marshallese church events.

An eVLP cytomegalovirus (CMV) vaccine was found to be safe and immunogenic at very low doses in healthy seronegative adults.